Psoriasis Awareness Month at Central BioHub

Psoriasis Awareness Month 2023 at Central BioHub

Psoriasis Awareness Month 2023 at Central BioHub

Psoriasis is more than just a skin rash – about 2-3% of the worldwide population suffer from this immune-mediated disease, but the causes of this disease remain unknown and there is currently no definite cure available.

This chronic inflammatory autoimmune skin condition is characterized by red, shedding spots on the skin and influenced by genetic and environmental factors. The pathogenesis of psoriasis involves the interplay between abnormal keratinocytes proliferation, immune cells, and other skin-resident cells. The primary form of psoriasis is psoriasis vulgaris, but the inflammation can also affect the joints and lead to psoriatic arthritis. Psoriasis is associated with co-morbidities such as cardiovascular diseases and metabolic syndromes.

Challenges in Psoriasis treatment with conventional formulations

Historically, the most used drugs for the treatment of psoriasis had been methotrexate (MTX), cyclosporine (CsA), acitretin, dexamethasone, and salicylic acid. However, due to poor absorptive capacity and other issues such as inconsistent drug release characteristics or retention of drug molecules in the target tissue in conventional formulations, the clinical efficacy of these drugs is restricted. Advances in topical nanocarriers allow the development of prominent drug delivery platforms which can be employed to address the above-mentioned issues associated with conventional formulations.

Biological therapies target immune pathways to treat Psoriasis

Other than that, biological therapies which target immune pathways like the IL-23/Th17 axis or cytokines like TNF-α are also available, as well as cheaper biosimilars. TNF-α is a cytokine that plays a key role in inflammation. Certain biomedical drugs make use of this and block the action of TNF- α, therefore decreasing the inflammation process and slowing the characteristic rapid skin cell turnover in psoriasis.

Likewise, interleukins are proteins involved in immune response. Therapeutic antibodies and other biological drugs aim to inhibit specific interleukins like IL-17A, IL-23, and IL-12/23, which have been shown to have a remarkable effect on the outcome of psoriasis treatment.

Another group of biological drugs are interleukin receptor antagonists. These drugs bind to receptors on immune cells such as the IL-17 receptor, hence preventing the interleukin to bind and thereby blocking the signalling cascade which causes the overwhelming inflammation response.

Advances in Psoriasis research enhance treatment options

The therapeutical spectrum for the treatment of psoriasis is expected to expand with the development of new small molecules such as JAK inhibitors and RORγt inhibitors, that target specific pathways involved in psoriasis pathogenesis.

Genetic factors are crucial for understanding disease predispositions and play an important role for the profiling of psoriatic types based on certain cytokine signatures. On top of that, identifying novel therapy response markers is also an important area of study to optimize psoriasis treatment options.

Central BioHub offers over 2000 human blood samples with confirmed psoriasis diagnosis that were tested for multiple laboratory parameters such as erythrocyte sedimentation rate (ESR) or anti-cyclic citrullinated peptides (CCP). Scientists worldwide can order psoriasis samples and use them for research studies that aim to expand the biomedical understanding and therapeutical window of psoriasis treatment.

Browse our inventory and order your research samples today:

Psoriasis Samples:

https://centralbiohub.de/biospecimens/dermatological-diseases/psoriasis

Directly accessible specimen information, fast and easy shipment, and scientific customer support that will answer all your questions make Central BioHub the number one online marketplace for human biomaterials. Browse the biggest catalogue for biospecimen and find the sample that best fits your needs by clicking on clinical diagnosis, icd-10-cm codes, and laboratory parameters.

Central BioHub - Order biospecimens online.

How does Psoriasis evolve in the body?

The pathogenesis of psoriasis involves a complex interaction of multiple cell types, including keratinocytes, dendritic cells, T cells, and neutrophils, which result in an abnormal cell proliferation pattern. Disturbances in the innate and adaptive immune responses play a key role in the development of psoriatic inflammation.

Which pathways and molecules are targeted in Psoriasis treatment?

While targeted therapies have shown high clinical efficacy in inhibiting IL-23 and IL-17, psoriasis is still a treatable but non curable disease. Other drugs targeting TNF-a and interleukin receptors aim to stop the inflammation. Central BioHub supports scientists investigating these pathways with well-characterized high quality psoriasis samples that can be utilized for research.

Which forms of Psoriasis can occur?

The primary form of psoriasis is psoriasis vulgaris, but the inflammation can also affect the joints and lead to psoriatic arthritis. Guttate Psoriasis is characterized by small, drop-shaped lesions that often develop after a bacterial or viral infection and affects mostly children. Other forms of psoriasis include inverse psoriasis, pustular psoriasis, nail psoriasis or erythrodermic psoriasis.

What is the best way to treat Psoriasis?

Despite the efficacy of targeted therapies, broader-acting drugs are still commonly used due to economic factors, dosage regimes, and adverse effects. Central BioHub aims to expand the field of psoriasis treatment by supplying researchers worldwide with human serum and plasma samples originating from psoriasis patients.